Gubra A/S (CPH:GUBRA)

Market Cap	5.75B -13.0%
Revenue (ttm)	2.64B +892.2%
Net Income	1.69B
EPS	102.70
Shares Out	16.33M
PE Ratio	3.43
Forward PE	32.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,130
Open	350.80
Previous Close	352.00
Day's Range	346.40 - 353.80
52-Week Range	293.00 - 571.00
Beta	0.25
Analysts	Buy
Price Target	451.50 (+28.19%)
Earnings Date	Aug 20, 2026

About Gubra

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinfor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 300
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: GUBRA